Review anchor
Melanocyte-stimulating hormone receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Melanocyte-stimulating hormone receptor
CHEMBL3795
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Melanocyte-stimulating hormone receptor as ChEMBL target CHEMBL3795, mapped to UniProt Q01726. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3795
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q01726
Melanocyte-stimulating hormone receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Melanocyte-stimulating hormone receptor matters
Melanocyte-stimulating hormone receptor is reviewed as Melanocyte-stimulating hormone receptor (UniProt Q01726); Melanocyte-stimulating hormone receptor shows approved-linked disease relevance led by erythropoietic protoporphyria. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 7 approved drugs, 1390 compounds, and 304 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Melanocyte-stimulating hormone receptor
Melanocyte-stimulating hormone receptor Sequence length is 317 aa.
Review this target as Melanocyte-stimulating hormone receptor, mapped to UniProt Q01726. Sequence length is 317 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q01726
Protein
Disease context
erythropoietic protoporphyria
Melanocyte-stimulating hormone receptor shows approved-linked disease relevance led by erythropoietic protoporphyria. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AFAMELANOTIDE, AFAMELANOTIDE ACETATE, DERSIMELAGON.
Start review with erythropoietic protoporphyria because it currently carries approved-linked support. Linked drugs include AFAMELANOTIDE, AFAMELANOTIDE ACETATE, DERSIMELAGON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
3 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 7 approved drugs, 1390 compounds, and 304 assays for this target. The dominant activity type is EC50. CHEMBL3898758 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL3898758 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
7 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Melanocyte-stimulating hormone receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q01726, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why erythropoietic protoporphyria is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1390
Total Compounds
304
Total Assays
7
Approved Drugs
IC50: 475.0, KI: 597.0, EC50: 956.0, KD: 4.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3898758
|
11.0 | EC50 | — |
|
|
No preferred name
CHEMBL3920516
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL3928766
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL3972160
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL3975096
|
11.0 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
SETMELANOTIDE
CHEMBL3301624
|
2020 |
|
|
BREMELANOTIDE
CHEMBL2070241
|
2019 |
|
|
AFAMELANOTIDE
CHEMBL441738
|
2014 |
Source Header